SCHEMBL95660

SCHEMBL95660

CCOC(=O)[CH]Cc1ccc(Cl)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.45
ALDH1A1 P00352 5/20 0.45
LMNA P02545 3/20 0.45
CYP1A2 P05177 2/20 0.45
CYP3A4 P08684 2/20 0.45
NPSR1 Q6W5P4 2/20 0.45
CYP2C19 P33261 1/20 0.45
HTT P42858 1/20 0.45
SMN1; SMN2 Q16637 3/20 0.44
ABCB11 O95342 1/20 0.44
TSHR P16473 1/20 0.44
HTR2A P28223 1/20 0.44
PMP22 Q01453 1/20 0.44
PPARA Q07869 1/20 0.44
TP53 P04637 2/20 0.43
OPRK1 P41145 1/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
GAA P10253 2/20 0.43
TDP1 Q9NUW8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11750979 0.84 CA12 (0.56) MAPTALDH1A1LMNACYP3A4SMN1; SMN2
SCHEMBL27505937 0.83 MAPT (0.49) MAPTALDH1A1LMNACYP1A2NPSR1
SCHEMBL290693 0.82 MAPT (0.51) MAPTALDH1A1LMNASMN1; SMN2TSHR
SCHEMBL3755931 0.82 ALDH1A1 (0.47) ALDH1A1CYP1A2CYP2C19RAB9AGAA
SCHEMBL7088412 0.77 NPSR1 (0.48) MAPTALDH1A1LMNACYP1A2CYP3A4
SCHEMBL11233379 0.75 CA12 (0.49) MAPTALDH1A1LMNACYP1A2CYP3A4
SCHEMBL7347631 0.75 MAPT (0.50) MAPTALDH1A1LMNACYP1A2CYP3A4
SCHEMBL703931 0.73 MAPT (0.72) MAPTALDH1A1TSHRNPC1RAB9A
SCHEMBL3268819 0.72 SMN1; SMN2 (0.55) MAPTALDH1A1LMNACYP1A2CYP3A4
Ethyl 3-(4-Chlorophenyl)Acrylate SCHEMBL14415942 0.72 CA12 (0.73) MAPTLMNACYP1A2CYP3A4KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200172491-A1 SUBSTITUTED 5-(HET-)ARYLPYRAZOLAMIDES AND SALTS THEREOF AND THEIR USE AS HERBICIDAL ACTIVE SUBSTANCES BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) 2020-06-04 US claimed
EP-3655393-A1 SUBSTITUTED 5-(HET-)ARYLPYRAZOLAMIDES AND SALTS THEREOF AND THEIR USE AS HERBICIDAL ACTIVE SUBSTANCES Bayer CropScience Aktiengesellschaft (DE) 2020-05-27 EP claimed
CN-110891941-A Substituted 5- (hetero) arylpyrazolamides and their salts and their use as herbicidally active substances 拜耳作物科学股份公司 2020-03-17 CN claimed
WO-2019016069-A1 SUBSTITUTED 5-(HET-)ARYLPYRAZOLAMIDES AND SALTS THEREOF AND THEIR USE AS HERBICIDAL ACTIVE SUBSTANCES BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) 2019-01-24 WO claimed
US-8362252-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-01-29 US disclosed
EP-1797082-B1 CARBOSTYRIL COMPOUND OTSUKA PHARMA CO LTD (JP) 2012-08-29 EP disclosed
EP-2426128-A1 Carbostyril compound Otsuka Pharmaceutical Co., Limited (JP) 2012-03-07 EP disclosed
CN-101068810-B Carbostyril compound OTSUKA PHARMA CO LTD 2011-02-09 CN disclosed
US-20100261705-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. 2010-10-14 US disclosed
US-7777038-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-08-17 US disclosed
US-20090326008-A1 NF-kappa B Inhibitor OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-12-31 US disclosed
EP-2043644-A1 NF- B INHIBITOR Otsuka Pharmaceutical Co., Ltd. (JP) 2009-04-08 EP disclosed
WO-2008010601-A1 NF- ϰB INHIBITOR OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2008-01-24 WO disclosed
CN-101068810-A Carbostyril compound OTSUKA PHARMA CO LTD (JP) 2007-11-07 CN disclosed
US-20070179173-A1 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-02 US disclosed
EP-1797082-A1 CARBOSTYRIL COMPOUND Otsuka Pharmaceutical Company, Limited (JP) 2007-06-20 EP disclosed
WO-2006035954-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200172491-A1 SUBSTITUTED 5-(HET-)ARYLPYRAZOLAMIDES AND SALTS THEREOF AND THEIR USE AS HERBICIDAL ACTIVE SUBSTANCES CYP4Z1, CYP3A5, CYP4X1 MAPT 4681/4885ALDH1A1 570/4885LMNA 4408/4885
US-20090326008-A1 NF-kappa B Inhibitor NFKBIA, NFKB2, IKBKB MAPT 4112/4885ALDH1A1 2948/4885LMNA 3740/4885
US-20070179173-A1 Carbostyril compound GTF2F1, F3, GTF2F2 MAPT 4773/4885ALDH1A1 2458/4885LMNA 4860/4885
US-20100261705-A1 CARBOSTYRIL COMPOUND GTF2F1, F3, GTF2F2 MAPT 4773/4885ALDH1A1 2458/4885LMNA 4860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.